New study eyes selexipag for neglected form of lung hypertension

This study looks at how well the oral medication selexipag works over the long term for people with a specific type of lung hypertension caused by schistosomiasis (a parasitic infection). Researchers will compare patients who received selexipag as part of routine care to similar patients who did not get the drug before it was available. The goal is to see if selexipag helps delay worsening of the disease, such as hospitalizations or need for stronger treatments. About 30 adults will be included, and no extra treatments or tests are given—just analysis of existing medical records.